Comparing samples of PDA patients treated with neoadjuvant chemotherapy with treatment naïve samples, we observed a statistically significant increase in activated CD8+ and CD4+ TRM cells with treatment, characterized by high CD103, CD127, CD69, and PD-1 expression. Here, CD4 is linked to Patent ductus arteriosus.